An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ:NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced.

San Diego, CA -- (SBWire) -- 06/02/2022 --Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties.

Investors who purchased shares of NeoGenomics, Inc. (NASDAQ: NEO) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain NeoGenomics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

NeoGenomics, Inc. reported that its annual Total Revenue rose from $408.83 million in 2019 to $444.44 million in 2020, and that its Net Income declined from $8 million in 2019 to $4.17 million in 2020.

On November 4, 2021, NeoGenomics, Inc. reported its third quarter financial results. In addition, NeoGenomics announced a "leadership team transition". NeoGenomics said that its current CFO led the company through multiple acquisitions, financing events, and navigated the company through the financial challenges associated with the COVID-19 global pandemic and will be namad Chief Sustainability and Risk Officer as of January 1, 2022. NeoGenomics said that William Bonello, who currently is NeoGenomics' President of its Informatics Division, will be named CFO as of January 1, 2022.

On March 28, 2022, NeoGenomics, Inc. announced that its Chief Executive Officer "will step down as CEO and member of the Board, effective immediately." NeoGenomics, Inc. also announced that it "expects revenue for Q1 2022 may be below the low end of its prior guidance of $118 - $120 million and EBITDA for Q1 2022 will be below the low end of its prior guidance of $(15) - $(12) million." NeoGenomics disclosed that "[t]he larger than anticipated EBITDA loss was primarily driven by higher than anticipated Clinical Services cost of goods sold" and that it "has withdrawn its 2022 annual financial guidance issued February 23, 2022."

Shares of NeoGenomics, Inc. (NASDAQ: NEO) declined from $47.13 per share on November 1, 2021, to as low as $7.66 per share on May 25, 2022.

Those who purchased shares of NeoGenomics, Inc. (NASDAQ: NEO) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Christopher Clausen
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

About The Shareholders Foundation
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.